CD19 and acute lymphoblastic leukemia: Taking advantage of this, Ruella et al. developed CD19/CD123 CAR-T cells and proved its ability to completely eradicate the primary B-ALL blasts (CD19+CD123+ and CD19-CD123+) and to prevent the CD19 antigen loss relapse in an immunodeficient (NSG) mouse model (25).